Prognostic relevance of tumor-infiltrating lymphocytes and immune checkpoints in pediatric medulloblastoma

References

• Nederlandse Kankerregistratie beheerd door IKNL ©. Cijfers over kanker (text in Dutch) http://www.cijfersoverkanker.nl/kinderen-en-kanker-55.html [accessed April 26, 2016].
   Google Scholar
• Ramaswamy V, Remke M, Bouffet E, Bailey S, Clifford SC, Doz F, Kool M, Dufour C, Vassal G, Milde T, et al. Risk stratification of childhood medulloblastoma in the molecular era: the current consensus. Acta Neuropathol. 2016;131:821–31. doi:10.1007/s00401-016-1569-6. PMID:27040285.
   PubMed Web of Science ®Google Scholar
• Packer RJ, Vezina G. Management of and prognosis with medulloblastoma: therapy at a crossroads. Arch Neurol. 2008;65:1419–24. doi:10.1001/archneur.65.11.1419. PMID:19001159.
   PubMedGoogle Scholar
• Packer RJ, Zhou T, Holmes E, Vezina G, Gajjar A. Survival and secondary tumors in children with medulloblastoma receiving radiotherapy and adjuvant chemotherapy: results of Children's Oncology Group trial A9961. Neuro Oncol. 2013;15:97–103. doi:10.1093/neuonc/nos267. PMID:23099653.
   PubMed Web of Science ®Google Scholar
• Diller L, Chow EJ, Gurney JG, Hudson MM, Kadin-Lottick NS, Kawashima TI, Leisenring WM, Meacham LR, Mertens AC, Mulrooney DA, et al. Chronic disease in the Childhood Cancer Survivor Study cohort: a review of published findings. J Clin Oncol. 2009;27:2339–55. doi:10.1200/JCO.2008.21.1953. PMID:19364955.
   PubMed Web of Science ®Google Scholar
• Fridman WH, Pages F, Sautes-Fridman C, Galon J. The immune contexture in human tumours: impact on clinical outcome. Nat Rev Cancer. 2012;12:298–306. doi:10.1038/nrc3245. PMID:22419253.
   PubMed Web of Science ®Google Scholar
• Motz GT, Santoro SP, Wang LP, Garrabrant T, Lastra RR, Hagemann IS, Lal P, Feldman MD, Benencia F, Coukos G. Tumor endothelium FasL establishes a selective immune barrier promoting tolerance in tumors. Nat Med. 2014;20:607–15. doi:10.1038/nm.3541. PMID:24793239.
   PubMed Web of Science ®Google Scholar
• Muldoon LL, Soussain C, Jahnke K, Johanson C, Siegal T, Smith QR, Hall WA, Hynynen K, Senter PD, Peereboom DM, et al. Chemotherapy delivery issues in central nervous system malignancy: a reality check. J Clin Oncol. 2007;25:2295–305. doi:10.1200/JCO.2006.09.9861. PMID:17538176.
   PubMed Web of Science ®Google Scholar
• Phoenix TN, Patmore DM, Boop S, Boulos N, Jacus MO, Patel YT, Roussel MF, Finkelstein D, Goumnerova L, Perreault S, et al. Medulloblastoma Genotype Dictates Blood Brain Barrier Phenotype. Cancer Cell. 2016;29:508–22. doi:10.1016/j.ccell.2016.03.002. PMID:27050100.
   PubMed Web of Science ®Google Scholar
• Junttila MR, de Sauvage FJ. Influence of tumour micro-environment heterogeneity on therapeutic response. Nature. 2013;501:346–54. doi:10.1038/nature12626. PMID:24048067.
   PubMed Web of Science ®Google Scholar
• Pham CD, Flores C, Yang C, Pinheiro EM, Yearley JH, Sayour EJ, Pei Y, Moore C, McLendon RE, Huang J, et al. Differential Immune Microenvironments and Response to Immune Checkpoint Blockade among Molecular Subtypes of Murine Medulloblastoma. Clin Cancer Res. 2016;22:582–95. doi:10.1158/1078-0432.CCR-15-0713. PMID:26405194.
   PubMed Web of Science ®Google Scholar
• Griesinger AM, Birks DK, Donson AM, Amani V, Hoffman LM, Waziri A, Wang M, Handler MH, Foreman NK. Characterization of distinct immunophenotypes across pediatric brain tumor types. J Immunol. 2013;191:4880–8. doi:10.4049/jimmunol.1301966. PMID:24078694.
   PubMed Web of Science ®Google Scholar
• Igney FH, Krammer PH. Immune escape of tumors: apoptosis resistance and tumor counterattack. J Leukoc Biol. 2002;71:907–20. PMID:12050175.
   PubMed Web of Science ®Google Scholar
• Raffaghello L, Nozza P, Morandi F, Camoriano M, Wang X, Garre ML, Cama A, Basso G, Ferrone S, Gambini C, et al. Expression and functional analysis of human leukocyte antigen class I antigen-processing machinery in medulloblastoma. Cancer Res. 2007;67:5471–8. doi:10.1158/0008-5472.CAN-06-4735. PMID:17545629.
   PubMed Web of Science ®Google Scholar
• Gerosa MA, Amadori G, Semenzato P, Gasparotto G, Carteri A. Immunobiology of primary CNS tumors in infancy and childhood. B- and T-cell dependent immunity and cytotoxicity and cell kinetic evaluation. Childs Brain. 1980;6:92–102. PMID:6965475.
   PubMedGoogle Scholar
• Liu D, Song L, Brawley VS, Robison N, Wei J, Gao X, Tian G, Margol A, Ahmed N, Asgharzadeh S, et al. Medulloblastoma expresses CD1 d and can be targeted for immunotherapy with NKT cells. Clin Immunol. 2013;149:55–64. doi:10.1016/j.clim.2013.06.005. PMID:23891738.
   PubMed Web of Science ®Google Scholar
• Vermeulen JF, van Hecke W, Spliet WG, Villacorta Hidalgo J, Fisch P, Broekhuizen R, Bovenschen N. Pediatric Primitive Neuroectodermal Tumors of the Central Nervous System Differentially Express Granzyme Inhibitors. PLoS One. 2016;11:e0151465. doi:10.1371/journal.pone.0151465. PMID:26963506.
   PubMed Web of Science ®Google Scholar
• Bovenschen N, Kummer JA. Orphan granzymes find a home. Immunol Rev. 2010;235:117–27. doi:10.1111/j.0105-2896.2010.00889.x. PMID:20536559.
   PubMed Web of Science ®Google Scholar
• Sapoznik S, Hammer O, Ortenberg R, Besser MJ, Ben-Moshe T, Schachter J, Markel G. Novel anti-melanoma immunotherapies: disarming tumor escape mechanisms. Clin Dev Immunol. 2012;2012:818214. doi:10.1155/2012/818214. PMID:22778766.
   PubMedGoogle Scholar
• van Houdt IS, Oudejans JJ, van den Eertwegh AJ, Baars A, Vos W, Bladergroen BA, Rimoldi D, Muris JJ, Hooijberg E, Gundy CM, et al. Expression of the apoptosis inhibitor protease inhibitor 9 predicts clinical outcome in vaccinated patients with stage III and IV melanoma. Clin Cancer Res. 2005;11:6400–7. doi:10.1158/1078-0432.CCR-05-0306. PMID:16144945.
   PubMed Web of Science ®Google Scholar
• van Kempen PM, Noorlag R, Swartz JE, Bovenschen N, Braunius WW, Vermeulen JF, Van Cann EM, Grolman W, Willems SM. Oropharyngeal squamous cell carcinomas differentially express granzyme inhibitors. Cancer Immunol Immunother. 2016;65:575–85. doi:10.1007/s00262-016-1819-4. PMID:26993499.
   PubMed Web of Science ®Google Scholar
• Pardoll DM. The blockade of immune checkpoints in cancer immunotherapy. Nat Rev Cancer. 2012;12:252–64. doi:10.1038/nrc3239. PMID:22437870.
   PubMed Web of Science ®Google Scholar
• Parsa AT, Waldron JS, Panner A, Crane CA, Parney IF, Barry JJ, Cachola KE, Murray JC, Tihan T, Jensen MC, et al. Loss of tumor suppressor PTEN function increases B7-H1 expression and immunoresistance in glioma. Nat Med. 2007;13:84–8. doi:10.1038/nm1517. PMID:17159987.
   PubMed Web of Science ®Google Scholar
• Brahmer JR, Tykodi SS, Chow LQ, Hwu WJ, Topalian SL, Hwu P, Drake CG, Camacho LH, Kauh J, Odunsi K, et al. Safety and activity of anti-PD-L1 antibody in patients with advanced cancer. N Engl J Med. 2012;366:2455–65. doi:10.1056/NEJMoa1200694. PMID:22658128.
   PubMed Web of Science ®Google Scholar
• Goldberg SB, Gettinger SN, Mahajan A, Chiang AC, Herbst RS, Sznol M, Tsiouris AJ, Cohen J, Vortmeyer A, Jilaveanu L, et al. Pembrolizumab for patients with melanoma or non-small-cell lung cancer and untreated brain metastases: early analysis of a non-randomised, open-label, phase 2 trial. Lancet Oncol. 2016;17:976–983. doi:10.1016/S1470-2045(16)30053-5. PMID:27267608.
   PubMed Web of Science ®Google Scholar
• Harter PN, Bernatz S, Scholz A, Zeiner PS, Zinke J, Kiyose M, Blasel S, Beschorner R, Senft C, Bender B, et al. Distribution and prognostic relevance of tumor-infiltrating lymphocytes (TILs) and PD-1/PD-L1 immune checkpoints in human brain metastases. Oncotarget. 2015;6:40836–49. doi:10.18632/oncotarget.5696. PMID:26517811.
   PubMed Web of Science ®Google Scholar
• Berghoff AS, Kiesel B, Widhalm G, Rajky O, Ricken G, Wohrer A, Dieckmann K, Filipits M, Brandstetter A, Weller M, et al. Programmed death ligand 1 expression and tumor-infiltrating lymphocytes in glioblastoma. Neuro Oncol. 2015;17:1064–75. doi:10.1093/neuonc/nou307. PMID:25355681.
   PubMed Web of Science ®Google Scholar
• Nduom EK, Wei J, Yaghi NK, Huang N, Kong LY, Gabrusiewicz K, Ling X, Zhou S, Ivan C, Chen JQ, et al. PD-L1 expression and prognostic impact in glioblastoma. Neuro Oncol. 2016;18:195–205. doi:10.1093/neuonc/nov172. PMID:26323609.
   PubMed Web of Science ®Google Scholar
• Garber ST, Hashimoto Y, Weathers SP, Xiu J, Gatalica Z, Verhaak RG, Zhou S, Fuller GN, Khasraw M, de Groot J, et al. Immune checkpoint blockade as a potential therapeutic target: surveying CNS malignancies. Neuro Oncol. 2016;18:1357–66. doi:10.1093/neuonc/now132. PMID:27370400.
   PubMed Web of Science ®Google Scholar
• Dorand RD, Nthale J, Myers JT, Barkauskas DS, Avril S, Chirieleison SM, Pareek TK, Abbott DW, Stearns DS, Letterio JJ, et al. Cdk5 disruption attenuates tumor PD-L1 expression and promotes antitumor immunity. Science. 2016;353:399–403. doi:10.1126/science.aae0477. PMID:27463676.
   PubMed Web of Science ®Google Scholar
• Murata D, Mineharu Y, Arakawa Y, Liu B, Tanji M, Yamaguchi M, Fujimoto KI, Fukui N, Terada Y, Yokogawa R, et al. High programmed cell death 1 ligand-1 expression: association with CD8+ T-cell infiltration and poor prognosis in human medulloblastoma. J Neurosurg. 2017;5:1–7. doi:10.3171/2016.11.JNS16991. PMID:28474991.
   PubMed Web of Science ®Google Scholar
• Aoki T, Hino M, Koh K, Kyushiki M, Kishimoto H, Arakawa Y, Hanada R, Kawashima H, Kurihara J, Shimojo N, et al. Low Frequency of Programmed Death Ligand 1 Expression in Pediatric Cancers. Pediatr Blood Cancer. 2016;63:1461–4. doi:10.1002/pbc.26018. PMID:27135656.
   PubMed Web of Science ®Google Scholar
• CCMO website:. Central Committee on Research involving Human Subjects (Centrale Commissie Mensgebonden Onderzoek) (text in Dutch): http://www.ccmo.nl/nl/uw-onderzoek-wmo-plichtig-of-niet [accessed September 2, 2017].
   Google Scholar
• van Diest PJ. No consent should be needed for using leftover body material for scientific purposes. For. BMJ. 2002;325:648–51. doi:10.1136/bmj.325.7365.648.
   PubMed Web of Science ®Google Scholar
• Hovestadt V, Remke M, Kool M, Pietsch T, Northcott PA, Fischer R, Cavalli FM, Ramaswamy V, Zapatka M, Reifenberger G, et al. Robust molecular subgrouping and copy-number profiling of medulloblastoma from small amounts of archival tumour material using high-density DNA methylation arrays. Acta Neuropathol. 2013;125:913–6. doi:10.1007/s00401-013-1126-5. PMID:23670100.
   PubMed Web of Science ®Google Scholar
• Brandes M, Willimann K, Moser B. Professional antigen-presentation function by human gammadelta T Cells. Science. 2005;309:264–8. doi:10.1126/science.1110267. PMID:15933162.
   PubMed Web of Science ®Google Scholar
• Chien YH, Meyer C, Bonneville M. Gammadelta T cells: first line of defense and beyond. Annu Rev Immunol. 2014;32:121–55. doi:10.1146/annurev-immunol-032713-120216. PMID:24387714.
   PubMed Web of Science ®Google Scholar
• Kmiecik J, Zimmer J, Chekenya M. Natural killer cells in intracranial neoplasms: presence and therapeutic efficacy against brain tumours. J Neurooncol. 2014;116:1–9. doi:10.1007/s11060-013-1265-5. PMID:24085644.
   PubMed Web of Science ®Google Scholar
• Poli A, Kmiecik J, Domingues O, Hentges F, Blery M, Chekenya M, Boucraut J, Zimmer J. NK cells in central nervous system disorders. J Immunol. 2013;190:5355–62. doi:10.4049/jimmunol.1203401. PMID:23687193.
   PubMed Web of Science ®Google Scholar
• Uldrich AP, Le Nours J, Pellicci DG, Gherardin NA, McPherson KG, Lim RT, Patel O, Beddoe T, Gras S, Rossjohn J, et al. CD1 d-lipid antigen recognition by the gammadelta TCR. Nat Immunol 2013;14:1137–45. doi:10.1038/ni.2713. PMID:24076636.
   PubMed Web of Science ®Google Scholar
• Ahmadzadeh M, Johnson LA, Heemskerk B, Wunderlich JR, Dudley ME, White DE, Rosenberg SA. Tumor antigen-specific CD8 T cells infiltrating the tumor express high levels of PD-1 and are functionally impaired. Blood. 2009;114:1537–44. doi:10.1182/blood-2008-12-195792. PMID:19423728.
   PubMed Web of Science ®Google Scholar
• Zhou Q, Munger ME, Veenstra RG, Weigel BJ, Hirashima M, Munn DH, Murphy WJ, Azuma M, Anderson AC, Kuchroo VK, et al. Coexpression of Tim-3 and PD-1 identifies a CD8+ T-cell exhaustion phenotype in mice with disseminated acute myelogenous leukemia. Blood. 2011;117:4501–10. doi:10.1182/blood-2010-10-310425. PMID:21385853.
   PubMed Web of Science ®Google Scholar
• Alexandrov LB, Nik-Zainal S, Wedge DC, Aparicio SA, Behjati S, Biankin AV, Bignell GR, Bolli N, Borg A, Borresen-Dale AL, et al. Signatures of mutational processes in human cancer. Nature. 2013;500:415–21. doi:10.1038/nature12477. PMID:23945592.
   PubMed Web of Science ®Google Scholar
• Majzner RG, Simon JS, Grosso JF, Martinez D, Pawel BR, Santi M, Merchant MS, Geoerger B, Hezam I, Marty V, et al. Assessment of programmed death-ligand 1 expression and tumor-associated immune cells in pediatric cancer tissues. Cancer. 2017;123:3807–15. doi:10.1002/cncr.30724. PMID:28608950.
   PubMed Web of Science ®Google Scholar
• Tumeh PC, Harview CL, Yearley JH, Shintaku IP, Taylor EJ, Robert L, Chmielowski B, Spasic M, Henry G, Ciobanu V, et al. PD-1 blockade induces responses by inhibiting adaptive immune resistance. Nature. 2014;515:568–71. doi:10.1038/nature13954. PMID:25428505.
   PubMed Web of Science ®Google Scholar
• Wolfl M, Jungbluth AA, Garrido F, Cabrera T, Meyen-Southard S, Spitz R, Ernestus K, Berthold F. Expression of MHC class I, MHC class II, and cancer germline antigens in neuroblastoma. Cancer Immunol Immunother. 2005;54:400–6. doi:10.1007/s00262-004-0603-z. PMID:15449039.
   PubMed Web of Science ®Google Scholar
• Perez-Martinez A, Fernandez L, Diaz MA. The therapeutic potential of natural killer cells to target medulloblastoma. Expert Rev Anticancer Ther. 2016;16:573–6. doi:10.1080/14737140.2016.1184978. PMID:27144504.
   PubMed Web of Science ®Google Scholar
• Fernandez L, Portugal R, Valentin J, Martin R, Maxwell H, Gonzalez-Vicent M, Diaz MA, de Prada I, Perez-Martinez A. In vitro Natural Killer Cell Immunotherapy for Medulloblastoma. Front Oncol. 2013;3:94. doi:10.3389/fonc.2013.00094. PMID:23626949.
   PubMedGoogle Scholar
• Silvani A, Salmaggi A, Parmiani G, Boiardi A. Successful adoptive immunotherapy with lymphokine-activated killer cells in the treatment of medulloblastoma disseminated via cerebrospinal fluid: case report. Neurosurgery. 1994;34:1078–80 ; discussion 80–1. doi:10.1227/00006123-199406000-00021. PMID:8084395.
   PubMed Web of Science ®Google Scholar
• Okamoto Y, Shimizu K, Tamura K, Miyao Y, Yamada M, Matsui Y, Tsuda N, Takimoto H, Hayakawa T, Mogami H. An adoptive immunotherapy of patients with medulloblastoma by lymphokine-activated killer cells (LAK). Acta Neurochir (Wien). 1988;94:47–52. doi:10.1007/BF01406615. PMID:3177046.
   PubMed Web of Science ®Google Scholar
• Shimizu K, Tamura K, Yamada M, Okamoto Y, Miyao Y, Park K, Matsui Y, Hayakawa T, Takimoto H, Mogami H. [Adoptive immunotherapy in patients with medulloblastoma by LAK cells]. No To Shinkei. 1989;41:991–5. PMID:2605046.
   PubMedGoogle Scholar
• Castriconi R, Dondero A, Negri F, Bellora F, Nozza P, Carnemolla B, Raso A, Moretta L, Moretta A, Bottino C. Both CD133+ and CD133- medulloblastoma cell lines express ligands for triggering NK receptors and are susceptible to NK-mediated cytotoxicity. Eur J Immunol. 2007;37:3190–6. doi:10.1002/eji.200737546. PMID:17918205.
   PubMed Web of Science ®Google Scholar
• Willmes C, Kumar R, Becker JC, Fried I, Rachakonda PS, Poppe LM, Hesbacher S, Schadendorf D, Sucker A, Schrama D, et al. SERPINB1 expression is predictive for sensitivity and outcome of cisplatin-based chemotherapy in melanoma. Oncotarget. 2016;7:10117–32. doi:10.18632/oncotarget.6956. PMID:26799424.
   PubMed Web of Science ®Google Scholar
• Blank C, Brown I, Peterson AC, Spiotto M, Iwai Y, Honjo T, Gajewski TF. PD-L1/B7 H-1 inhibits the effector phase of tumor rejection by T cell receptor (TCR) transgenic CD8+ T cells. Cancer Res. 2004;64:1140–5. doi:10.1158/0008-5472.CAN-03-3259. PMID:14871849.
   PubMed Web of Science ®Google Scholar
• Dong Y, Sun Q, Zhang X. PD-1 and its ligands are important immune checkpoints in cancer. Oncotarget. 2017;8:2171–86. doi:10.18632/oncotarget.13895. PMID:27974689.
   PubMed Web of Science ®Google Scholar
• Brahmer J, Reckamp KL, Baas P, Crino L, Eberhardt WE, Poddubskaya E, Antonia S, Pluzanski A, Vokes EE, Holgado E, et al. Nivolumab versus Docetaxel in Advanced Squamous-Cell Non-Small-Cell Lung Cancer. N Engl J Med. 2015;373:123–35. doi:10.1056/NEJMoa1504627. PMID:26028407.
   PubMed Web of Science ®Google Scholar
• Ferris RL, Blumenschein G, Jr., Fayette J, Guigay J, Colevas AD, Licitra L, Harrington K, Kasper S, Vokes EE, Even C, et al. Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck. N Engl J Med. 2016;375:1856–67. doi:10.1056/NEJMoa1602252. PMID:27718784.
   PubMed Web of Science ®Google Scholar
• Larkin J, Chiarion-Sileni V, Gonzalez R, Grob JJ, Cowey CL, Lao CD, Schadendorf D, Dummer R, Smylie M, Rutkowski P, et al. Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma. N Engl J Med. 2015;373:23–34. doi:10.1056/NEJMoa1504030. PMID:26027431.
   PubMed Web of Science ®Google Scholar
• Diggs LP, Hsueh EC. Utility of PD-L1 immunohistochemistry assays for predicting PD-1/PD-L1 inhibitor response. Biomark Res. 2017;5:12. doi:10.1186/s40364-017-0093-8. PMID:28331612.
   PubMed Web of Science ®Google Scholar
• Hirsch FR, McElhinny A, Stanforth D, Ranger-Moore J, Jansson M, Kulangara K, Richardson W, Towne P, Hanks D, Vennapusa B, et al. PD-L1 Immunohistochemistry Assays for Lung Cancer: Results from Phase 1 of the Blueprint PD-L1 IHC Assay Comparison Project. J Thorac Oncol. 2017;12:208–22. doi:10.1016/j.jtho.2016.11.2228. PMID:27913228.
   PubMed Web of Science ®Google Scholar